- Home
- SNGX vs BFRI Comparison
SNGX vs BFRI Comparison
Compare SNGX & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- BFRI
- Stock Information
- Founded
- SNGX 1987
- BFRI 1997
- Country
- SNGX United States
- BFRI United States
- Employees
- SNGX N/A
- BFRI N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- BFRI Health Care
- Exchange
- SNGX Nasdaq
- BFRI Nasdaq
- Market Cap
- SNGX 7.4M
- BFRI 6.2M
- IPO Year
- SNGX 1987
- BFRI 2021
- Fundamental
- Price
- SNGX $2.43
- BFRI $1.11
- Analyst Decision
- SNGX
- BFRI Strong Buy
- Analyst Count
- SNGX 0
- BFRI 1
- Target Price
- SNGX N/A
- BFRI $7.00
- AVG Volume (30 Days)
- SNGX 31.1K
- BFRI 158.3K
- Earning Date
- SNGX 03-14-2025
- BFRI 03-14-2025
- Dividend Yield
- SNGX N/A
- BFRI N/A
- EPS Growth
- SNGX N/A
- BFRI N/A
- EPS
- SNGX N/A
- BFRI N/A
- Revenue
- SNGX $364,183.00
- BFRI $35,358,000.00
- Revenue This Year
- SNGX N/A
- BFRI $17.69
- Revenue Next Year
- SNGX $76.64
- BFRI $19.71
- P/E Ratio
- SNGX N/A
- BFRI N/A
- Revenue Growth
- SNGX N/A
- BFRI 5.17
- 52 Week Low
- SNGX $1.83
- BFRI $0.65
- 52 Week High
- SNGX $14.88
- BFRI $2.43
- Technical
- Relative Strength Index (RSI)
- SNGX 46.06
- BFRI 49.87
- Support Level
- SNGX $2.35
- BFRI $1.06
- Resistance Level
- SNGX $2.47
- BFRI $1.16
- Average True Range (ATR)
- SNGX 0.13
- BFRI 0.07
- MACD
- SNGX 0.04
- BFRI -0.00
- Stochastic Oscillator
- SNGX 61.36
- BFRI 55.00
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.